Evidence map›Paper›PMID 28739185›Full record

ArticleNutrition, metabolism, and cardiovascular diseases : NMCD2017

Novel atherogenic pathways from the differential transcriptome analysis of diabetic epicardial adipose tissue.

V Camarena, D Sant, M Mohseni, T Salerno, M L Zaleski, G Wang, G Iacobellis

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 65 citations in OpenAlex.

  1. Review
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Benefits of GLP-1 Mimetics on Epicardial Adiposity.Current medicinal chemistry · 2023
    Article
  17. Review
  18. Epicardial adipose tissue in contemporary cardiology.Nature reviews. Cardiology · 2022 · on this map
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

V CamarenaJohn P. Hussman Institute for Human Genomics, Dr. John T. Macdonald Foundation Department of Human Genetics, Miami, FL, USA.
D SantJohn P. Hussman Institute for Human Genomics, Dr. John T. Macdonald Foundation Department of Human Genetics, Miami, FL, USA.
M MohseniDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Miami, FL, USA.
T SalernoDepartment of Surgery, Division of Thoracic and Cardiac Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
M L ZaleskiDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Miami, FL, USA.
G WangJohn P. Hussman Institute for Human Genomics, Dr. John T. Macdonald Foundation Department of Human Genetics, Miami, FL, USA. Electronic address: gwang@med.miami.edu.
G IacobellisDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, Miami, FL, USA. Electronic address: giacobellis@med.miami.edu.
Dr. John T. Macdonald Foundation · USUniversity of Miami · US

Funding

Epigenetic Prevention of Diabetic Neuropathy by Vitamin CR01NS089525 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WANG, GAOFENG · 2014 to 2017
$1.2M
NINDS NIH HHS R01 NS089525
6 · The paper itself

Abstract

BACKGROUND AND

aimTo evaluate the epicardial adipose tissue (EAT) transcriptome in comparison to subcutaneous fat (SAT) in coronary artery disease (CAD) and type 2 diabetes (T2DM). METHODS AND

resultsSAT and EAT samples were obtained from subjects with T2DM and CAD (n = 5) and those without CAD with or without T2DM (=3) undergoing elective cardiac surgery. RNA-sequencing analysis was performed in both EAT and SAT. Gene enrichment analysis was conducted to identify pathways affected by the differentially expressed genes. Changes of top genes were verified by quantitative RT-PCR (qRT-PCR), western blot, and immunofluorescence. A total of 592 genes were differentially expressed in diabetic EAT, whereas there was no obvious changes in SAT transcriptome between diabetics and non-diabetics. Diabetic EAT was mainly enriched in inflammatory genes, such as Colony Stimulating Factor 3 (CSF3), Interleukin-1b (IL-1b), IL-6. KEGG pathway analysis confirmed that upregulated genes were involved in inflammatory pathways, such as Tumor Necrosis Factor (TNF), Nuclear Factor-κB (NF-κB) and advanced glycation end-products-receptor advanced glycation end products (AGE-RAGE). The overexpression of inflammatory genes in diabetic EAT was largely correlated with upregulated transcription factors such as NF-κB and FOS.

conclusionsDiabetic EAT transcriptome is significantly different when compared to diabetic SAT and highly enriched with genes involved in innate immune response and endothelium, like Pentraxin3 (PTX3) and Endothelial lipase G (LIPG). EAT inflammatory genes expression could be induced by upregulated transcription factors, mainly NF-kB and FOSL, primarily activated by the overexpressed AGE-RAGE signaling. This suggests a unique and novel atherogenic pathway in diabetes.

Indexed as

TranscriptomeAdipokinesAdipose TissueAgedAtherosclerosisCoronary Artery DiseaseCross-Sectional StudiesCytokinesDiabetes Mellitus, Type 2Diabetic AngiopathiesFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansInflammationMaleAdipokinesCytokinesRNA, MessengerEpicardial adipose tissueEpicardial fatTranscriptome

Identifiers

PMID28739185
PMCPMC7540222
OpenAlexW2623528424

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.